In a study of men with cT4 prostate cancer, definitive local treatment of the primary tumor site was associated with improved castration resistance-free survival.
A recent study has shed light on the potential benefits of definitive local therapy in improving survival outcomes for patients with cT4 prostate cancer. The findings, which are based on a retrospective study of 154 patients, suggest that this approach could be a game-changer in the treatment of advanced prostate cancer.
HCN Medical Memo
As healthcare professionals, these findings present us with a new perspective on treating advanced prostate cancer. The significant improvement in survival rates associated with definitive local therapy underscores its potential as a viable treatment option. This could lead to a paradigm shift in our approach to managing this disease, ultimately improving patient care and outcomes.
- The study was conducted by Chad Tang, MD, MS, of The University of Texas MD Anderson Cancer Center in Houston, and colleagues.
- The patient cohort was heterogeneous with 54% having metastatic cT4N0-1M1 disease; 24% had regionally advanced cT4N1M0; and 22% had localized cT4N0M0.
- Definitive local therapy was associated with significantly improved 5-year overall survival rates: 57% vs 31% without local therapy.
- Sensitivity analyses revealed significantly higher local recurrence-free survival rates (76% vs 58%), castration resistance-free survival rates (58% vs 40%), and disease-free survival rates (45% vs 29%).
- Definitive local therapy was associated with a 42% lower risk for all-cause mortality in the overall cohort.
For men with advanced prostate cancer, the survival rates significantly decrease. Specifically, for those with distant spread of prostate cancer, the average five-year survival rate is approximately 28-32%. This is much lower than the survival rates for local and regional stages of prostate cancer.
More in Urology